LANSING, Mich., March 19, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fibers, announced today that the cocoons from the first stage of its Monster Silk™ pilot production program ("program") have been reeled into threads of the Company's recombinant spider silk as the program moves into an advanced state.
Additionally, the silkworm hatchlings from the second stage of the program have now spun cocoons that are made of Monster Silk™.
"The pilot production program has advanced well ahead of our expectations. At this rate, we will be facing some near term decisions regarding the launching of commercial production. In my opinion, we are now reaching major milestones every two to three weeks. We are undergoing tremendous developmental changes, which we believe will lead to substantial growth of our business over the next few months," said Company founder and CEO, Kim Thompson.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
Source:Kraig Biocraft Laboratories, Inc